CClinicalTrials.gg
Not yet recruitingNCT07384728RandomizedUpdated Feb 3, 2026

Ramadan Experience of Individuals With Type 2 Diabetes

An interventional study of The effect of fasting and not fasting during Ramadan. in Type 2 Diabetes, sponsored by Dilan aktepe coşar. Not yet recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Dilan aktepe coşar · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Feb 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to examine the effects of fasting during Ramadan on treatment adherence, psychological adjustment, and glycemic control in individuals with type 2 diabetes. While Ramadan fasting is a religious practice, it can also pose health risks such as hypoglycemia, hyperglycemia, and metabolic imbalance in individuals with diabetes. Adherence to treatment and self-care, as well as psychosocial adjustment, are crucial in the effective management of diabetes. Given that a large portion of Turkey's population is Muslim, comparing individuals with type 2 diabetes who fast and those who do not during Ramadan will contribute to improving patient care within a cultural and religious context. The findings of this study are expected to guide nurses in developing personalized, culturally sensitive care plans tailored to the needs of individuals before, during, and after Ramadan.

Read the detailed description

Fasting during Ramadan is a religious practice observed globally by adult Muslims. Individuals fast during Ramadan due to an emotional and spiritual connection to the holy month. Fasting involves abstaining from food, drink, and oral medications for a month, between sunrise and sunset each year. The duration of Ramadan fasting varies between 10 and 19 hours depending on geographical and seasonal conditions. While this is a religious practice, those who fast may experience various health risks, particularly for individuals with type 1 and type 2 diabetes.

Diabetes mellitus is an insidious chronic metabolic disease characterized by high blood sugar levels that cause serious damage to all body systems over time. Diabetes is a chronic disease that has increased in recent years and leads to morbidity, loss of productivity, decreased quality of life, and mortality in individuals due to various complications. Adherence to treatment plays a critical role in the treatment, care, and management of chronic diseases.

According to the WHO, adherence to treatment in diabetic patients is defined as a self-care process that includes home blood sugar monitoring, regulation of food consumption, medication use, regular physical activity, foot care, regular visits to the doctor for periodic check-ups, and dental care. Individuals who adhere to treatment in chronic diseases can exhibit effective coping skills, avoid psychological problems, experience fewer negative emotions, implement healthy lifestyle changes, and maintain control over their health status.

The psychological aspect of chronic diseases is often underestimated. Although it is assumed that most patients adapt well to the psychological aspects of chronic diseases, it becomes more difficult to adapt psychologically when patients experience deficiencies in their physical health status. Diabetes is a chronic disease that leads to mental and cognitive problems in addition to physiological complications, and it takes time to cope with it. Therefore, understanding the psychosocial adaptation to the disease in individuals with diabetes will guide nurses in positively influencing disease management and preventing or delaying possible complications. In addition, fasting negatively affects individuals with diabetes physically, socially, and psychologically. Glycemic control before Ramadan is considered a key determinant of fasting safety in individuals with diabetes.

In light of this information, and given that the Turkish population is predominantly Muslim, this study aims to examine the effects of fasting and non-fasting during Ramadan on treatment adherence, psychological adjustment, and glycemic control in individuals with Type 2 diabetes. The results of this study are expected to guide healthcare professionals, particularly nurses who have the most contact with patients, in understanding cultural and religious practices before, during, and after Ramadan to provide personalized care tailored to patients' needs. Through this study, we aimed to identify effective strategies to improve both treatment adherence and psychological adjustment by positively impacting the treatment, care, and management of diabetic patients

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • Ramadan experience
  • Treatment
  • Psychological
  • Glycemic control
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's planned enrollment of 70 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Dilan aktepe coşar is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Individuals ≥18 years of age

Able to give informed consent

Diagnosed with type 2 diabetes

Planning to fast during Ramadan

Exclusion criteria

Exclusion Criteria:

Presence of psychiatric illness

Presence of cognitive impairment

Receiving additional treatments that significantly affect glucose levels (e.g., ongoing steroid therapy)

Individuals who have decided not to fast during Ramadan

Individuals who have stopped fasting during Ramadan

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Experimental group: Individuals observing the fast.

    Patients in the experimental group received face-to-face dietary education from the researcher in the waiting room for approximately 15 minutes, and were given an "Information Brochure." Pre-education (pre-test) data collection tools were administered to diabetic patients. All data collection tools were administered to these patients, except for the structured Patient Information Form, which was completed one month after Ramadan 2026.

    Other: The effect of fasting and not fasting during Ramadan.

  • No intervention
    No Intervention: Control Group

    Diabetic patients in this group were classified as a non-fasting group. No intervention was applied. Only data collection forms were administered before the study (pre-test) and after Ramadan 2026.

Interventions

  • OtherThe effect of fasting and not fasting during Ramadan.

    The effects of fasting and non-fasting during Ramadan on treatment adherence, psychological adjustment, and glycemic control.

    Also known as: The effect of fasting during Ramadan

06

What researchers measure

Primary outcomes

  1. 1. Parametre

    HbA1c 2-4 weeks before Ramadan (basic assessment).

    Time frame: 2-4 weeks

  2. 2. Parametre

    Treatment Adherence Scale, 2-4 weeks before Ramadan This scale was developed to evaluate "Patient Adherence in Type 2 Diabetes Mellitus Treatment." Validity and reliability analyses have shown it to be a valid and reliable scale. Based on the scores obtained from the scale, adherence is considered good if patients are doing what they should and not doing what they shouldn't, despite factors affecting treatment adherence. The scale: * Is administered to patients with type 2 diabetes for at least one year. • Consists of 30 items in total. * A 5-point Likert scale is used for scoring. • Patients indicate the most appropriate option for each statement on the scale using a 5-point Likert scale (Strongly agree=1, Agree=2, Partially agree=3, Disagree=4, and Strongly disagree=5). • The scale contains 13 items representing positive attitudes and 17 items representing negative attitudes. In scoring, positive items (1, 3, 5, 8, 13, 15, 16, 17, 19, 23, 25, 26, 29) are scor

    Time frame: 2-4 weeks

  3. 3. Parametre

    Psychological and Adherence Impact Scale 2-4 weeks before Ramadan. The BASE-6 was developed by Cruz et al. (2019) and it is a self-report instrument of general psychological adjustment comprising of six items. Each item assesses how a participant has been feeling in the past week. Items are rated on a 7-point scale (ranging from 1 = Not at all to 5 = Extremely). A sample item is "To what extent have you felt irritable, angry, and/or resentful this week?". Using three different adult samples, the original study demonstrated good internal consistency (α = .87-.93) and test-retest reliability (intraclass correlation was .77) over one-week period.

    Time frame: 2-4 weeks

  4. Post-Ramadan 2. Parametre

    Treatment adherence will be assessed using the Treatment Adherence Scale for Type 2 Diabetes Mellitus, a validated and reliable 30-item, 5-point Likert scale. Patients rate each item from strongly agree to strongly disagree. Higher scores indicate better adherence to diabetes treatment.

    Time frame: Post-Ramadan: 1-2 months after

Secondary outcomes

  1. Post-Ramadan 1. Parametre

    Post-Ramadan: 1-2 months after the end of fasting (follow-up). Measurements: HbA1c

    Time frame: Post-Ramadan: 1-2 months after

  2. Post-Ramadan 3. Parametre

    Post-Ramadan: 1-2 months after the end of fasting (follow-up). Measurements: The BASE-6 was developed by Cruz et al. (2019) and it is a self-report instrument of general psychological adjustment comprising of six items. Each item assesses how a participant has been feeling in the past week. Items are rated on a 7-point scale (ranging from 1 = Not at all to 5 = Extremely). A sample item is "To what extent have you felt irritable, angry, and/or resentful this week?". Using three different adult samples, the original study demonstrated good internal consistency (α = .87-.93) and test-retest reliability (intraclass correlation was .77) over one-week period.

    Time frame: Post-Ramadan: 1-2 months after

07

Study locations

2 sites
  • Gümüşhane Universıty
    Gümüşhane, Kelkit 2900, Turkey (Türkiye)
  • Gümüşhane Üniversitesi
    Gümüşhane, Kelkit 29100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual patient data will not be shared due to the need to protect participant confidentiality, the privacy of personal health information, and compliance with applicable ethical committee approval and data protection legislation (KVKK). Data will only be analyzed for scientific purposes in an anonymized and aggregated form, and there are no plans to share raw data containing individually identifying information with third parties. This approach has been adopted to protect participant rights and ensure compliance with ethical research principles.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384728
Lead sponsor
Dilan aktepe coşar
Collaborators
Gümüşhane Universıty
Responsible party
Dilan aktepe coşar (lecture, Gümüşhane Universıty) — Sponsor-investigator
First posted
Feb 3, 2026
Start date
Jan 3, 2026 (estimated)
Primary completion
Feb 20, 2026 (estimated)
Completion
Mar 20, 2026 (estimated)
Last update
Feb 3, 2026

Study contacts

Dilan aktepe coşar, PhD
Contact
dilan_aktepe@hotmail.com
+905075935875 ext. 4149
Hatice Demirağ, PhD
Contact
hatice_etbas@hotmail.com
05534267394 ext. 4445
Dilan aktepe coşar, PhD
study director · Gümüşhane Universıty

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion